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Summary
Introduction: Hyperprolactinemia is a common side-effect of antipsychotic treatment. Antipsy-
chotics and hyperprolactinemia are both considered risk factors of metabolic disturbances
and diabetes. Investigations on prolactin response to meal ingestion in antipsychotic-treated
patients are missing.
Material and methods: In a case-control design, 49 antipsychotic-treated, clinically stable, non-
diabetic, schizophrenia spectrum male patients were compared with 93 healthy male controls
by age (33.1, SD 7.4 vs. 32.9, SD 6.6 years), body mass index (26.2, SD 4.6 vs. 26.1, SD 3.9 kg/m2)
and waist circumference (96.4, SD 13.0 vs. 96.7, SD 11.9 cm). Serum-prolactin was measured
in the morning and 90min after ingestion of a standardized liquid meal (2268 kJ).
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Results: Fasting prolactin levels varied considerably, and mean fasting prolactin levels did not
signiﬁcantly differ between patients and controls (12.33, SD 11.58 vs. 10.06, SD 8.67 ng/ml,
p = 0.623). In the controls, postprandial serum prolactin was signiﬁcantly reduced ( −2.53, SD
9.75 ng/ml, p = 0.016). In antipsychotic-treated patients postprandial serum prolactin tended to
increase ( 2.62, SD 10.96 ng/ml, p = 0.081). Analyses of subgroups based on the prolactinogenic
liability of their antipsychotic treatment indicated 22 to 65% higher postprandial prolactin levels
with high and intermediate prolactinogenic antipsychotics.
Discussion: A physiological postprandial suppression of serum prolactin appears absent in
antipsychotic-treated males. Marked variability in fasting prolactin levels may reﬂect individual
variations in the diurnal cycle. Uniform acquisition procedures accounting for diurnal variation
and food intake may enhance reliability of prolactin levels in antipsychotic-treated male patients.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The introduction of antipsychotic medication has indis-
putably improved the clinical outcome of patients with
schizophrenia and related psychotic disorders, but the treat-
ment is frequently associated with side-effects. Whereas the
management of extra-pyramidal and metabolic side-effects
has attracted considerable clinical attention, hyperpro-
lactinemia is a common, but less investigated side-effect
of antipsychotic treatment.
Prolactin is a pituitary hormone involved in reproduc-
tion, endothelial function, immune modulation, hair, skin
and bone regulation, and metabolism (Marano and Ben-
Jonathan, 2014). Prolactin is secreted in a circadian rhythm
with approximately 19 pulses in 24 h and peaks during
sleep (Roelfsema et al., 2012). Due to circadian variation,
serum prolactin is normally sampled between 0800 h and
1000 h. Prolactin level <20—25 ng/ml is considered normal,
regardless of variations between assays, gender differences
(women >men), and elevations associated with increased
body weight (Roelfsema et al., 2012).
Antipsychotics and hyperprolactinemia are both risk fac-
tors of metabolic disturbances and diabetes (Arslan et al.,
2014; Yavuz et al., 2003), but to what extent prolactin lev-
els are associated with food intake in antipsychotic-treated
patients is unknown. Previous reports on the physiological
prolactin response to meal ingestion are scarce, small, and
results are conﬂicting, possibly also reﬂecting differences
in nutrition content between studies. The hitherto largest
study in 20 healthy volunteers recently showed that pro-
lactin decreases after meal ingestion (Plumelle et al., 2014),
but earlier studies have reported both unchanging (Goettler
et al., 1990), and increasing levels (Carlson et al., 1983;
Ishizuka et al., 1983).
The clinical effect as well as the extrapyramidal side-
effects of antipsychotic drugs are linked to the degree
of dopamine D2 receptor blockade in striatum (Kapur and
Seeman, 2001). In the pituitary, blockade of the dopamine
D2 receptors leads to an increased release of prolactin
resulting in clinical hyperprolactinemia (Meltzer and Fang,
1976). Since the anterior pituitary gland is located outside
of the blood brain barrier, especially antipsychotics with low
lipophilicity, high peripheral-to-central dopamine D2 recep-
tor occupancy ratio, and high dopamine D2 receptor afﬁnity,
e.g. perphenazine, risperidone, and amisulpride are prone
to induce hyperprolactinemia (McKeage and Plosker, 2004).
Conversely, treatment with aripiprazole, quetiapine, and
clozapine is associated with lower risk of hyperprolactine-
mia, while ziprasidone and olanzapine appear to assume an
intermediate position (Leucht et al., 2013).
Here we investigate fasting and postprandial serum
prolactin levels in a sample of non-diabetic antipsychotic-
treated male patients and matched healthy controls.
Associations between prolactin levels and high, interme-
diate and low prolactinogenic antipsychotic treatment are
explored.
2. Methods
The study was approved by the Committee on Biomedical
Research Ethics for the Capital Region of Denmark (H-C-
2007-0069), the Danish Data Protection Agency, and the
Danish Medicines Agency (2602-706). The study was reg-
istered at ClinicalTrials.gov (NCT00627757), conducted in
accordance with the Declaration of Helsinki II, carried out
according to Good Clinical Practice (GCP), and monitored
by the GCP of Unit Copenhagen University Hospital. Partic-
ipants received written and verbal information about the
study and gave written informed consent prior to enroll-
ment.
2.1. Participants
We included 49 antipsychotic-treated, clinically stable, non-
diabetic male patients and 93 healthy male controls in the
age of 18—45 years. Details of inclusion and exclusion crite-
ria and participants were previously reported (Ebdrup et al.,
2014). In short, patients had a diagnosis in the schizophre-
nia spectrum [ICD-10 diagnosis: F20, F21, F22, F25, F28,
F60.1] and all were Caucasian outpatients treated with at
least one antipsychotic. Controls were recruited by adver-
tisement and were matched on age, body mass index (BMI),
waist circumference, and race.
Based on the assumed prolactinogenic effect of the
antipsychotic treatment (Leucht et al., 2013; McKeage and
Plosker, 2004), we divided patients into three subgroups:
a high (perphenazine, amisulpride, risperidone) (n = 7), an
intermediate (olanzapine, ziprasidone) (n = 14), and a low
prolactinogenic subgroup (aripiprazole, clozapine, quetiap-
ine) (n = 25). Six patients, who were treated with more than
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one antipsychotic drug, were excluded from the subgroup
analyses.
2.2. Experimental procedures
Subjects were fasting as well as tobacco and alcohol absti-
nent for at least 8 h prior to baseline blood sampling, which
was performed between 0730 h and 1030 h. After baseline
sampling, each subject received a 360ml liquid meal (66.2 g
carbohydrates, 21.6 g proteins and 20.9 g fat [2268 kJ];
Nutricia Nutridrink, Nutricia A/S, Allerød, Denmark) over
10min. Postprandial blood samples were collected after
90min and plasma was stored at −80 ◦C until analyses.
2.3. Analyses
Prolactin was measured with a chemiluminescence
immunoassay on Immulite 2500 instrument using L5KPR2
reagents (Siemens, Deerﬁeld, IL, USA) calibrated toward
WHO 3rd IS 84/500 with maximal intra and inter-assay vari-
ation coefﬁcients of 3.6—7.4% and a limit of detection of
0.05 ng/ml according to the manufacturer’s speciﬁcations.
2.4. Statistics
Group comparisons for demographic data were performed
using independent t tests for continuous variables and Chi-
square tests for nominal or ordinal variables. Prolactin
values required logarithmic (log) transformation to obtain
normal distribution. We tested for main effects between
patients and controls with a repeated measures analysis
of variance (rmANOVA). We entered ‘Group’ (patient vs.
control) as between subject factor and ‘Meal’ (fasting vs.
postprandial prolactin values) as within subject factor. Sim-
ilarly, our subgroup analyses were done with rmANOVA.
Bonferroni post hoc analyses of signiﬁcant main effects
were performed with separate t tests. All statistical tests
were two-tailed and a signiﬁcance level of 0.05 was applied
throughout. Data were analyzed using Statistical Package for
the Social Science software (SPSS version 19, IBM Corpora-
tion, Armonk, NY, USA).
3. Results
3.1. Demographics
Patients and controls were males, well-matched on age
(33.1, SD 7.4, [range: 19—45 years] vs. 32.9, SD 6.6 years,
[range: 19—45 years]; p = 0.87), BMI (26.2, SD 4.6 vs. 26.1,
SD 3.9 kg/m2; p = 0.87), and waist circumference (96.4, SD
13.0 vs. 96.7, SD 11.9 cm; p = 0.43). Patients and controls
did not differ signiﬁcantly in glycated hemoglobin (HbA1c)
(5.6, SD 0.3 vs. 5.7, SD 0.3%; p = 0.68). More patients were
smokers (53 vs. 22%; p < 0.001), and patients were less phys-
ically active (<30min/day) (33 vs. 5%; p < 0.001) (see Ebdrup
et al., 2014 for details).
There were no signiﬁcant differences in age, BMI or waist
circumference between the three patient subgroups and
controls.
3.2. Prolactin
The rmANOVA showed a main effect of Group [F1, 140 = 6.77,
p = 0.019] as well as a signiﬁcant Group×Meal interaction
[F1, 140 = 2.37, p = 0.005]. Although the overall effect of Meal
was not signiﬁcant [F1, 140 = 0.02, p = 0.96], the signiﬁcant
group effect justiﬁed post hoc testing.
The mean fasting prolactin levels did not differ sig-
niﬁcantly between patients and controls (12.33, SD
11.58 ng/ml, [range: 0.9—53.4 ng/ml] vs. 10.06, SD
8.67 ng/ml, [range: 2.2—66.0 ng/ml], t = 0.49; p = 0.62).
Mean postprandial prolactin levels were signiﬁcantly higher
in patients compared to controls (14.95, SD 13.32 ng/ml
vs. 7.64, SD 3.88 ng/ml, t = 3.3; p = 0.002). This group
difference at the postprandial time point was explained by
a trend-level signiﬁcant increase in prolactin in patients
( 2.62, SD 10.96 ng/ml, t =−1.78, p = 0.081), along with a
signiﬁcant postprandial prolactin reduction in controls (
−2.53, SD 9.75 ng/ml, t = 2.45, p = 0.016) (Fig. 1).
The mean fasting and postprandial prolactin levels in
the three antipsychotic treatment subgroups were: 24.62,
SD 18.35 and 30.08, SD 19.24 ng/ml (high prolactinogenic
subgroup), 11.22, SD 10.02 and 18.56, SD 13.73 ng/ml (inter-
mediate prolactinogenic subgroup), and 8.68, SD 5.02 and
8.72, SD 5.15 ng/ml (low prolactinogenic subgroup). Thus,
the postprandial compared to the fasting prolactin levels
were 22% higher in the high prolactinogenic subgroup, 65%
higher in the intermediate prolactinogenic subgroup and
unchanged in the low prolactinogenic subgroup.
The rmANOVA showed a main effect of Subgroup
[F3, 131 = 13.249, p < 0.001], and a signiﬁcant Subgroup×Meal
interaction [F3, 131 = 3.889, p = 0.011]. The effect of Meal was
not signiﬁcant [F3, 131 = 2.509, p = 0.116].
Post hoc tests of the fasting state revealed a signiﬁcant
difference between high vs. low (t = 2.824, p = 0.009), and
high vs. control (t = 3.173, p = 0.002). Post hoc tests of the
postprandial state showed signiﬁcant differences between
high vs. low (t = 4.106, p < 0.001), high vs. control (t = 6.505,
p < 0.001), intermediate vs. low (t = 2.914, p = 0.006), and
intermediate vs. control (t = 4.932, p < 0.001) (Fig. 2).
Controlling for the variables, which we previously
reported signiﬁcantly different between patients and con-
trols (tobacco smoking, daily physical activity, as well
as fasting values of proinsulin, C-peptide, and glucose-
dependent insulinotropic polypeptide (GIP), total choles-
terol, low-density lipoprotein cholesterol, triglycerides,
and CRP, and postprandial values of insulin, proinsulin, C-
peptide, and GIP (Ebdrup et al., 2014)), did not alter the
ﬁndings.
4. Discussion
The present study supports that a decrease in serum pro-
lactin appears to be a physiological response to meal
ingestion (Plumelle et al., 2014). Conversely, this response
appears absent in antipsychotic-treated males, where serum
prolactin levels either remain stable or increase depending
on the prolactinogenic effect of the antipsychotic compound
(Figs. 1 and 2).
Fasting prolactin levels were similar in patients and
controls, though somewhat lower than in a previous
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Figure 1 shows serum prolactin levels at fasting state and 90min postprandially in patients and controls. Horizontal black bars
represent mean prolactin levels. * Meal ingestion signiﬁcantly reduced the prolactin level in controls (p = 0.016). ** Mean postprandial
prolactin levels were signiﬁcantly higher in patients compared to controls (p = 0.002).
report on fasting prolactin in antipsychotic-treated patients
(18 ng/ml) (Suzuki et al., 2013). This discrepancy may be
explained by the relatively few of our patients on high
prolatinogenic antipsychotics (15%), whereas the interme-
diate (37%) and particularly the low (54%) prolatinogenic
groups were larger. Accordingly, the absence of sig-
niﬁcant differences in fasting prolactin levels between
subgroups may therefore reﬂect a type 2 error in these
analyses. Nevertheless, we observed signiﬁcantly ele-
vated fasting prolactin levels in patients treated with
high prolatinogenic compounds compared to patients
treated with low prolatinogenic compounds and between
controls.
Our data and subgroup analyses indicate a hierarchical
effect of antipsychotics on prolactin levels: The higher the
prolatinogenic liability of an antipsychotic compound, the
higher the fasting level of prolactin. Although the prolactin
increase was more marked with intermediate (65%) than
with high prolactinogenic compounds (22%), the prolactin
levels signiﬁcantly and hierarchically separated at the post-
prandial time point (Fig. 2).
Some limitations apply to this study. Since fasting pro-
lactin was sampled at only one time point, we could not
control for ﬂuctuations in the diurnal cycle of prolactin
(Plumelle et al., 2014). Assessment of individual diurnal
variations would require fasting measurements at sev-
eral time points, and to our knowledge, no studies have
addressed this issue. Theoretically, our observed prolactin
differences at 90min could therefore reﬂect abnormal
antipsychotic-induced diurnal variations rather than effects
of meal. However, we would expect dyssynchronized pro-
lactin secretion to affect prolactin levels at any time
point. Since fasting prolactin levels did not differ between
groups, our data favors the interpretation that diurnal
variations is reﬂected in the marked inter-individual vari-
ations. Conversely, meal ingestion appears to drive the
observed postprandial intra-individual group differences.
With a half-life of approximately 40min (Yoshida et al.,
1991), we judge 90min appropriate to observe changes in
prolactin. The fact that both patients and controls were
examined in the morning and under identical conditions,
and the clear hierarchical effect of prolactinogenic antipsy-
chotic compounds on postprandial prolactin levels at the
postprandial time point (Fig. 2), support that we observe
pharmacological effects rather than merely diurnal vari-
ations. Due to gender variations in prolactin secretion
(Roelfsema et al., 2012), our ﬁndings may not apply to
females.
Postprandial prolactin suppression appears absent in antipsychotic-treated male patients 5
Figure 2 shows serum prolactin levels at fasting state and 90min postprandially in three subgroups of patients treated with high,
intermediate, and low prolactinogenic antipsychotics and in healthy controls. For illustration purpose, fasting and postprandial
mean values are connected by straight lines. Differences in the fasting state: high vs. low (p = 0.009), high vs. control (p = 0.002).
Differences in the postprandial state: high vs. low (p < 0.001), high vs. control (p < 0.001), intermediate vs. low (p = 0.006), and
intermediate vs. control (p < 0.001). Error bars represent standard error of the mean.
5. Conclusions
In antipsychotic-treated males, a physiological postpran-
dial suppression of serum prolactin appears absent. Marked
variability in fasting prolactin levels may reﬂect individual
variations in the diurnal cycle. In psychiatric practice, blood
samples of prolactin are often obtained without considering
diurnal variation or meal ingestion. Our data suggest that
uniform acquisition procedures (e.g. morning sampling and
fasting state) may enhance reliability of prolactin levels in
antipsychotic-treated male patients.
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